Taipei Times: How does Ginko International Co (金可國際) look at its sales and profitability this year, as the economy is recovering from a global slowdown?
Tsai Kuo-chou (蔡國洲): We are upbeat about the industry’s outlook improving. Last quarter, the company set up two production lines in China and three production lines in Taiwan.
We might start full operation of those lines next quarter, which will significantly boost the company’s manufacturing capacity.
Last year, the company’s revenue grew more than 20 percent from a year earlier, while net profits jumped more than 40 percent.
We aim to have a stronger performance this year with sales increasing by double digits.
We expect our profit margin to remain comfortable, thanks to a high entry level for the business. We do not see any formidable rivals on the horizon.
TT: Will the company increase its headcount and capital expenditure to meet expectations of rising demand?
Tsai: We plan to add 300 workers to our payroll, which currently stands at 1,500 in both Taiwan and China, with more than 300 staff based at the Central Taiwan Science Park (中部科學園區).
We intend to increase our workforce here by 100 this year.
The company has invested NT$1.5 billion [US$51.7 million] in establishing five production lines in Taiwan after expanding local manufacturing facilities two years ago.
To better serve local consumers, we plan to produce high-end products here. Last year, we spent between NT$700 million and NT$800 million on new equipment. This year, we may spend a similar amount.
However, this year we will focus mainly on making colored contact lenses, which are gaining popularity and generate higher margins.
Such products are not for correcting eyesight, but are sold as fashion accessories.
The company also plans to develop a plot of land measuring 10,000 ping (33,000m2) in China this year and purchase new equipment in order to expand production facilities there.
TT: Ginko’s share price has outperformed its peers in the biotechnology sector listed on the GRETAI Securities Market as well as the Gretai index since its debut last year. Would you share the company’s growth secret?
Tsai: Established in the Cayman Islands in 2007, the company is devoted to the production of conventional contact lenses, disposable contact lenses and lens care products, targeting China as its main market.
The firm’s subsidiary, Haichang Contact Lens Co (海昌眼鏡), is a globally branded contact lens vendor and sells its eye care products under the Hydron brand in China.
Today, we command more than 30 percent of market share in China after proving the favorite branded contact lens among Chinese college students from 2008 onward.
We attribute the firm’s rapid growth to a [successful] business model by starting business in rural areas and then expanding into urban areas such as second-tier and fifth-tier cities.
The company spends sufficient resources on boosting its brand awareness and value by hiring pop singers Jolin Tsai (蔡依林) and Show Luo (羅志祥) to endorse its products, a marketing strategy that appears to have paid off as reflected in sales figures.
TT: Haichang was awarded “well-known trademark” status in China last month. How will the company benefit from this success?
Tsai: Haichang’s is the second well-known trademark the company has been awarded in China after Formosa Optical (寶島眼鏡).
Only four Taiwanese companies won this recognition in the second half of last year.
The status will help protect the company’s economic value as it allows quicker and easier access for the company to government interventions over brand piracy disputes. Brand piracy is a big headache for companies that aim for excellence [in China].
There are more than 3,000 different Formosa Optical outlets, including fake ones, in China.
Among them, we only own 1,300 outlets.
I walked by three Formosa Optical stores on the same street of a Chinese city, but none is legally authorized.
Haichang contact lenses are also the target of brand piracy. Hopefully, the Chinese authorities will step up its efforts to crack down on illegal use of trademarks in the future.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained